AGP Executive Report
Last update: 7 hours agoRett syndrome treatment in Europe: Acadia’s DAYBU (trofinetide) has received European Commission marketing authorization as the first and only EU-approved option for neurobehavioral symptoms of Rett syndrome for patients aged 5+ (including Liechtenstein, Iceland and Norway), with access now depending on country-by-country pricing and reimbursement. Breast cancer care expands in Liechtenstein region: The European Commission also authorized Gilead’s Trodelvy plus Merck’s Keytruda for first-line, PD-L1–positive metastatic triple-negative breast cancer (TNBC) across the EU plus Norway, Iceland and Liechtenstein, positioning Trodelvy as a backbone therapy across PD-L1 status. U.S. listing watch for Liechtenstein-linked markets: Hansa Biopharma is weighing a potential U.S. Nasdaq listing for imlifidase (Idefirix), after submitting draft SEC paperwork, as it continues to commercialize the kidney transplant desensitization drug in multiple European countries including Liechtenstein. Public health policy backdrop: The EU welcomed eight non-EU countries—including Liechtenstein—aligning with EU restrictive measures against Belarus, expanding the reach of sanctions tied to the Ukraine war.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
